Project Grant K99GM166944
- The National Institute of General Medical Sciences awarded Massachusetts Institute of Technology $438,788 in project grant funding on July 1, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to support research on microbial manipulation of eukaryotic membranes. The research examines how bacteria including Listeria monocytogenes and Rickettsia parkeri manipulate host cell membranes to disseminate through tissues and cross cellular compartments. The study focuses...
- The National Institute of General Medical Sciences awarded Massachusetts Institute of Technology $269,071 on July 1, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to develop and apply cryo-electron microscopy and cryo-electron tomography methods for visualizing protein machine assembly, function, and regulation at high resolution. The work emphasizes development of the CryoDRGN and TomoDRGN software ecosystem to enable structural analysis of complex samples in...
- The National Institute of General Medical Sciences awarded the University of Massachusetts $2.35 million on August 1, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to investigate non-specific electrostatic interactions of biological macromolecules in physiological and pathological processes. The project examines how highly charged polycationic and polyanionic biomacromolecules — including heparin, neutrophil extracellular traps, and other polymeric species —...
- The National Institute of General Medical Sciences awarded Massachusetts Institute of Technology $121,866 on August 21, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to develop open-source computational workflows for metabolite structural elucidation in untargeted metabolomics. The project will expand the ICEBERG geometric deep learning model to train on curated open-source datasets (GNPS, MassSpecGym) through knowledge distillation from proprietary models and...
- The National Institute of General Medical Sciences awarded Massachusetts Institute of Technology $300,196 on March 1, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to conduct structural investigations into the regulatory states of human ribonucleotide reductase using cryogenic electron microscopy. The project uses cryo-EM to determine structures of the human RNR protein in both active and inactive states. The first aim involves determining cryo-EM structures...
- The National Institute of General Medical Sciences awarded Northeastern University $440,000 on July 1, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to discover novel antimicrobial molecules from clostridial biosynthesis. The project characterizes cobalamin-dependent radical S-adenosylmethionine enzymes fused with non-ribosomal peptide synthetase adenylation domains found in clostridial genomes. The recipient will conduct biochemical characterization of these...
- The National Institute of General Medical Sciences awarded the Trustees of Boston University $437,036 on June 1, 2026, for genomic enzymology research to decipher bacterial membrane-associated glycan assembly under the Biomedical Research and Research Training program (CFDA 93.859). The funded work identifies and assigns functional signatures for substrate specificity in phosphoglycosy transferase and glycosyltransferase enzymes to enable glycan composition inference at the protein sequence...
- The National Institute of General Medical Sciences awarded $502,372 to Massachusetts Institute of Technology on July 1, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to develop selective, catalytic isomerization reactions that convert simple organic building blocks into complex organic molecules relevant to biomedical research. The work encompasses stereocenter editing—precise interconversion of stereoisomeric molecules at late synthetic stages to enable...
- The National Institute of General Medical Sciences, a component of the Department of Health and Human Services, awarded $440,465 to the Massachusetts Institute of Technology on July 1, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to develop biophysical models of genome folding and function. Over the five-year performance period ending February 28, 2031, the award funds research into chromosome architecture and the mechanisms that shape it—motor-driven loop...
- The National Institute of General Medical Sciences, part of the Department of Health and Human Services National Institutes of Health, awarded New York University $421,737 on March 10, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to develop data-driven, predictive biophysical models of molecular mechanisms underlying cellular quiescence in microorganisms. The research focuses on quantitative relations between physiological traits and molecular processes in...
The National Institute of General Medical Sciences awarded Massachusetts Institute of Technology $127,567 on September 3, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to investigate mechanisms of nuclease-based bacterial immunity systems. The research, carried out in Cambridge, Massachusetts, through August 31, 2028, combines genetic and molecular biology approaches with training in biochemistry, structural biology, and computational methods to dissect how bacteria deploy nucleases to defend against bacteriophages. The project pursues three aims: investigation of a membrane-bound nuclease that cleaves phage DNA during genome injection, including construction of chimeras between homologs targeting different phages; examination of a novel nuclease with an auxiliary domain resembling a phage virion component; and classification of a diverse panel of nucleases based on timing of cleavage, targeting specificity, and domain architecture to establish general principles of bacterial anti-phage immunity. The K99 phase focuses on career development and foundational mechanistic work, with Aim 3 pursued primarily during the R00 phase. This award is a Project Grant, the assistance type typical of investigator-initiated research under NIGMS's mission to support basic research advancing understanding of biological processes and laying the foundation for advances in disease diagnosis, treatment, and prevention.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $127.6k | 9/3/26 |